Pharma Focus Asia
KP - Sustainable Packaging Solutions

Roadmap to Biomarker Discovery: Innovations, Opportunities, and Breakthroughs


Vice President - Bioinformatics : Chandra Sekhar Pedamallu

Prinicipal Scientific Manager: Debasis Pore

Senior Scientific Manager II: Katyayni Vinnakota

Senior Technical Program Manager I: Harrisham Kaur, Meeta Sunil, Priyanka Shah,Priyanka Shah, Harrisham Kaur

Senior Scientific Manager I: Amrita Bhattacherjee, Govardhan Kothapalli Shroff

Technical Program Manager II: Hita Garapati

Technical Program Manager I: Nag Himakund Mallampalli, Praveen Korepu

Scientific Manager I: Mahendra Pal Singh, Snehal Dilip Karpe, Neha Kulkarni, Anjali Kumari, Aditya Mahadevan Iyer

Senior Scientific Specialist I: Shikha Roy, Tuhina Srivastava, Harshmi Shah, Ankush Jadhav

Senior Scientific Analyst II: Shylander Raju Tumiki

Group Head: Jitesh K. Pillai (Program Management), Puneet Saxena (Computational Biology), Uzma Saeed (Biology)


Biomarkers are indicators of homeostasis, disease states, or pharmacological interventions. An ideal biomarker must be binary (present or absent), quantifiable in tissues, cells, body fluids, or in simple physiological parameters such as blood sugar or blood pressure with minimal variability, should have substantial signal to noise ratio (sensitive and specific), and vary promptly and reliably in response to changes due to an underlying condition or treatment. The main benefits and limitations of biomarkers are summarized.

Also referred to as biological markers, molecular markers, surrogate endpoints, or signature molecules, biomarkers are of immense significance to biopharma, diagnostics, personalized medicine, and overall healthcare industry. The global biomarkers market valued at USD 66.97 billion in 2022 is expected to grow at a CAGR of 13.3% from 2023 to 2030. Variables such as enhanced impact of companion diagnostics, rise in incidence and prevalence of cancers, cardiovascular, neurological, and immunological diseases, higher private and public investments and funding, noteworthy inventions from current R&D, and novel digital health technology solutions are expected to disrupt and catapult the growth of the biomarker industry.

Biomarkers have a wide spectrum of functionalities, ranging from early drug discovery, to pre-clinical, and finally late-stage clinical development as depicted.

For more information click download PDF of the White Paper.

Connect with Excelra experts:

Download '.pdf' Format of the whitepaper.

Download Whitepapers
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024CPHI Chine || PMEC China 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024CPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?